Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
P/E ratio for Insmed Incorporated (INSM)
P/E ratio as of 2023: -5.81
According to Insmed Incorporated's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.81. At the end of 2022 the company had a P/E ratio of -5.11.
P/E ratio history for Insmed Incorporated from 1999 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.81 |
| 2022 | -5.11 |
| 2021 | -7.03 |
| 2020 | -11.05 |
| 2019 | -7.94 |
| 2018 | -3.11 |
| 2017 | -10.78 |
| 2016 | -4.64 |
| 2015 | -8.99 |
| 2014 | -8.41 |
| 2013 | -10.61 |
| 2012 | -4.29 |
| 2011 | -1.19 |
| 2010 | -12.99 |
| 2009 | 0.83 |
| 2008 | -3.64 |
| 2007 | -4.74 |
| 2006 | -1.49 |
| 2005 | -2.35 |
| 2004 | -3.17 |
| 2003 | -10.27 |
| 2002 | -0.40 |
| 2001 | -3.38 |
| 2000 | -0.80 |
| 1999 | -6.68 |